WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsCertara Inc (CERT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BrightSpring Health Services, Inc. Common Stock generates 3151% more annual revenue ($13.65B vs $419.75M). BTSG leads profitability with a 2.3% profit margin vs -3.6%. BTSG earns a higher WallStSmart Score of 53/100 (C-).

BTSG

Buy

53

out of 100

Grade: C-

Growth: 8.7Profit: 5.0Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.65

CERT

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.63
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BTSG.

CERTUndervalued (+55.5%)

Margin of Safety

+55.5%

Fair Value

$15.56

Current Price

$5.37

$10.19 discount

UndervaluedFair: $15.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
359.8%10/10

Earnings expanding 359.8% YoY

Revenue GrowthGrowth
25.6%8/10

Revenue surging 25.6% year-over-year

CERT2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.363/10

Elevated debt levels

P/E RatioValuation
79.2x2/10

Premium valuation, high expectations priced in

CERT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

Altman Z-ScoreHealth
1.634/10

Distress zone — elevated risk

Market CapQuality
$808.94M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 25.6% demonstrates continued momentum.

Bull Case : CERT

The strongest argument for CERT centers on Price/Book, Debt/Equity.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 79.2x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.

Bear Case : CERT

The primary concerns for CERT are Revenue Growth, Altman Z-Score, Market Cap.

Key Dynamics to Monitor

BTSG profiles as a growth stock while CERT is a turnaround play — different risk/reward profiles.

BTSG carries more volatility with a beta of 1.87 — expect wider price swings.

BTSG is growing revenue faster at 25.6% — sustainability is the question.

BTSG generates stronger free cash flow (101M), providing more financial flexibility.

Bottom Line

BTSG scores higher overall (53/100 vs 37/100) and 25.6% revenue growth. CERT offers better value entry with a 55.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, specializing in the care of diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation. The company is committed to delivering personalized, high-quality care through a skilled workforce, which contributes to improved patient outcomes and enhances quality of life. With a focus on strategic investments in innovative technologies and a robust approach to value-based care, BrightSpring is well-positioned to thrive in the dynamic healthcare environment and capitalize on emerging market opportunities.

Visit Website →

Certara Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.

Want to dig deeper into these stocks?